Genetic Modulation of Impaired Cardiac Conduction
Sodium Channel β4 Subunit Missing in Action
See related article, pages 1283–1292
Inherited disorders of heart rhythm and cardiac conduction have received tremendous attention during the past 15 years. The discovery of mutations in several genes, mostly encoding subunits of ion channels, has revealed the molecular basis for various familial arrhythmia susceptibility syndromes and enabled deployment of clinical genetic testing to identify at-risk persons. Proper risk stratification in these settings is crucial for selecting the most appropriate treatments for individual patients, but knowledge of the primary mutation does not always help predict risk of serious cardiac events.
With more widespread use of genetic testing in disorders such as the congenital long QT syndrome (LQTS) and Brugada syndrome (BrS) has come the recognition that not all mutation carriers are equally affected.1–4 When asymptomatic mutation carriers belong to a family that segregates a Mendelian phenotype (ie, caused by a single gene defect) such as LQTS, we say that the mutation exhibits “reduced” or “incomplete penetrance.” Similarly, certain mutations may confer variable risk of disease expression or variation in the signs and symptoms evident in related individuals (“variable expressivity”). Both incomplete penetrance and variable expressivity are likely attributable to genetic, environmental, or developmental factors that condition the host or help trigger disease onset. Genetic factors distinct from the primary disease-causing mutation are referred to as “modifiers.” Identification of genetic modifiers of Mendelian disorders may improve the precision of molecular diagnostics and provide additional clues about disease mechanism. However, the search for genetic modifiers can be quite challenging.
In this issue of Circulation Research, Remme et al report on a search for candidate genetic modifiers of a cardiac conduction disorder caused by mutation of the cardiac sodium channel gene, SCN5A.5 A specific mutation, in-frame insertion of an aspartic acid residue at position 1795 in the human protein (designated 1795insD), was previously identified by this group in a large Dutch family segregating a mixed phenotype of LQTS and BrS with additional features of bradycardia and impaired cardiac conduction.6 When the corresponding mutation is transgenically engineered in murine Scn5a (corresponding to 1798insD), the resulting heterozygous mice exhibit features of the human disorder including bradycardia, prolonged QT interval, and impaired cardiac conduction most evident in the right ventricle.7 Importantly, the investigators recognized that the severity of the cardiac conduction defect exhibited significant strain dependence when the mutation was transmitted to different inbred mouse lines. In particular, they observed that the conduction defect was less severe when the mutation was present in FVB/N mice than when the same allele was present on a 129P2 genomic background. Furthermore, flecainide aggravated bradycardia and QRS widening more in 129P2 than in FVB/N mutant mice. Because inbred mouse strains have been extremely well characterized genetically, the recognition of a strain-dependent phenotype provides an outstanding opportunity to map genes that contribute to variable phenotype.
To provide clues about the potential genetic basis for these phenotype disparities, Remme et al5 examined differences in gene expression between cardiac tissues obtained from the two inbred strains. Using microarray technology, the investigators discovered 76 genes that exhibited significantly different mRNA expression levels between the 2 strains. Approximately half of the genes were expressed at a higher level in the 129P2 mice as compared to FVB/N, whereas the other genes detected were expressed at a lower level. Inspecting this list of differentially expressed genes, the group discovered that Scn4b encoding a sodium channel accessory subunit (β4) was expressed at a substantially lower level in 129P2 mice. They further demonstrated that right ventricular tissue from 129P2 mice had very low levels of β4 protein. Logically, they considered the possibility that differential expression of β4 contributed to the strain-dependent conduction defect observed in Scn5a-1798insD mutant mice.
Differences in functional behavior of cardiac sodium current between the two mouse strains were also observed. Specifically, sodium currents recorded from 129P2 myocytes exhibited significant differences in the voltage-dependence of activation, a depolarized shift in the conductance-voltage relationship, compared with FVB/N myocytes. This finding suggested a potential biophysical mechanism for impaired conduction velocity (ie, insufficient sodium current activation), an idea corroborated using a computational approach. These findings provide indirect support for their hypothesis that Scn4b is a genetic modifier of impaired cardiac conduction.
Further proof of this hypothesis will require additional mouse genetic studies. If Scn4b is a dominant modifier of the murine phenotype, then genetic mapping studies should complement the finding of differential expression between strains by showing linkage to this locus. Alternatively, transgenic overexpression of Scn4b in 129P2 mice carrying Scn5a-1798insD may provide corroborative evidence if the strain differences in phenotype are eliminated. Importantly, there were 75 other differentially expressed genes between the 2 mouse strains. Although Scn4b is an attractive candidate modifier because of its known association with voltage-gated sodium channels, further studies should address the contribution of other differentially expressed genes on modulating the degree of impaired cardiac conduction. Perhaps these studies will reveal other previously unrecognized molecular pathways regulating cardiac conduction.
Sodium channel β subunit proteins come in four “flavors” (β1 through β4) encoded by distinct genes (SCN1B through SCN4B).8 Mutations in some β subunit genes have been linked to familial epilepsy and inherited disorders of heart rhythm thus emphasizing their likely physiological importance.9–11 The 4 β subunit genes are expressed widely in neuronal tissue, muscle, and heart, but there are no systematic biochemical data to indicate with which specific pore-forming α subunits they partner in various tissues. Expression of all 4 β subunit proteins has been demonstrated in mouse heart with 2 patterns of localization. The β1 and β3 subunits localize along the z-lines, suggesting expression in the t-tubules, whereas β2 and β4 have been shown to locate in punctate clusters in a subgroup of intercalated disks.12 How these distinct patterns of localization mediate the physiological actions of different β subunits in heart is not known.
In neuronal tissue, several functional activities have been ascribed to β subunits, including regulation of excitability, cell adhesion, neural development, and possibly control of transcription.8 Coexpression of β subunits with recombinant brain and heart sodium channel α subunits in heterologous cells causes subtle but significant alterations of functional properties.13,14 Relevant to the study by Remme et al,5 coexpression of β4 with cardiac sodium channels in vitro results in virtually no functional change in sodium current.15 However, these in vitro findings do not necessarily rule out important physiological activities for sodium channel β subunits in heart, a point emphasized by the discovery of a missense mutation in SCN4B associated with congenital LQTS.11
Although these reported mouse studies provide important new and interesting findings, an important next step for this research will be to determine whether SCN4B is a genetic modifier of human diseases associated with SCN5A mutations, including the original Dutch family segregating the 1795insD allele, and perhaps other inherited arrhythmias such as BrS. Ultimately, such studies will help shape new risk assessment strategies that consider the primary mutation as well as genetic modifiers.
Sources of Funding
Funded by NIH grants HL068880 and HL083374.
The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.
Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation. 1999; 99: 529–533.
Brink PA, Crotti L, Corfield V, Goosen A, Durrheim G, Hedley P, Heradien M, Geldenhuys G, Vanoli E, Bacchini S, Spazzolini C, Lundquist AL, Roden DM, George AL Jr, Schwartz PJ. Phenotypic variability and unusual clinical severity of congenital long-QT syndrome in a founder population. Circulation. 2005; 112: 2602–2610.
Priori SG, Napolitano C, Gasparini M, Pappone C, Della BP, Brignole M, Giordano U, Giovannini T, Menozzi C, Bloise R, Crotti L, Terreni L, Schwartz PJ. Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: a prospective evaluation of 52 families. Circulation. 2000; 102: 2509–2515.
Remme CA, Scicluna BP, Verkerk AO, Amin AS, van Brunschot S, Beekman L, Deneer VHM, Chevalier C, Oyama F, Miyazaki H, Nukina N, Wilders R, Escande D, Houlgatte R, Wilde AAM, Tan HL, Veldkamp MW, de Bakker JMT, Bezzina CR. Genetically determined differences in sodium current characteristics modulate conduction disease severity in mice with cardiac sodium channelopathy. Circ Res. 2009; 104: 1283–1292.
Bezzina C, Veldkamp MW, van Den Berg MP, Postma AV, Rook MB, Viersma JW, van Langen IM, Tan-Sindhunata G, Bink-Boelkens MT, Der Hout AH, Mannens MM, Wilde AA. A single Na+ channel mutation causing both long-QT and Brugada syndromes. Circ Res. 1999; 85: 1206–1213.
Remme CA, Verkerk AO, Nuyens D, van Ginneken AC, van BS, Belterman CN, Wilders R, van Roon MA, Tan HL, Wilde AA, Carmeliet P, de Bakker JM, Veldkamp MW, Bezzina CR. Overlap syndrome of cardiac sodium channel disease in mice carrying the equivalent mutation of human SCN5A-1795insD. Circulation. 2006; 114: 2584–2594.
Watanabe H, Koopmann TT, Le SS, Yang T, Ingram CR, Schott JJ, Demolombe S, Probst V, Anselme F, Escande D, Wiesfeld AC, Pfeufer A, Kaab S, Wichmann HE, Hasdemir C, Aizawa Y, Wilde AA, Roden DM, Bezzina CR. Sodium channel β1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest. 2008; 118: 2260–2268.
Medeiros-Domingo A, Kaku T, Tester DJ, Iturralde-Torres P, Itty A, Ye B, Valdivia C, Ueda K, Canizales-Quinteros S, Tusie-Luna MT, Makielski JC, Ackerman MJ. SCN4B-encoded sodium channel β4 subunit in congenital long-QT syndrome. Circulation. 2007; 116: 134–142.
Maier SK, Westenbroek RE, McCormick KA, Curtis R, Scheuer T, Catterall WA. Distinct subcellular localization of different sodium channel alpha and beta subunits in single ventricular myocytes from mouse heart. Circulation. 2004; 109: 1421–1427.
Isom LL, De Jongh KS, Patton DE, Reber BFX, Offord J, Charbonneau H, Walsh K, Goldin AL, Catterall WA. Primary structure and functional expression of the β1 subunit of the rat brain sodium channel. Science. 1992; 256: 839–842.
Yu FH, Westenbroek RE, Silos-Santiago I, McCormick KA, Lawson D, Ge P, Ferriera H, Lilly J, DiStefano PS, Catterall WA, Scheuer T, Curtis R. Sodium channel β4, a new disulfide-linked auxiliary subunit with similarity to β2. J Neurosci. 2003; 23: 7577–7585.